GREENFIELD, IN, BiomEdit, a pioneering animal health biotechnology company, announced a significant milestone in the development of BE-101, its lead candidate for the prevention of mortality associated with necrotic enteritis (NE) in broiler chickens. The product has entered the final phase of the U.S.

格林菲尔德，印第安纳州，BiomEdit，一家领先的动物健康生物技术公司，宣布其主要候选产品BE-101在预防与坏死性肠炎（NE）相关的肉鸡死亡率方面取得了重要的里程碑。该产品已进入美国的最后阶段。

Department of Agriculture's (USDA) conditional licensure process and is advancing toward commercialization, expected in 2026..

美国农业部 (USDA) 的有条件许可程序，并正在朝着预计在 2026 年实现的商业化迈进。

BiomEdit announced the successful close of its Series B financing, led by Anterra Capital, with follow-on investment from Nutreco and new participation from AgriZeroNZ, Indiana's Elevate Ventures, and Betagro Ventures, among others. The oversubscribed round (~$18.4M) provides sufficient capital to fund BiomEdit through conditional licensure and into the commercial launch of BE-101..

BiomEdit 宣布成功完成由 Anterra Capital 领投的 B 轮融资，Nutreco 跟进投资，AgriZeroNZ、印第安纳的 Elevate Ventures 和 Betagro Ventures 等新投资者也参与其中。此次超额认购的融资轮（约 1840 万美元）为 BiomEdit 提供了足够的资金，以支持其通过条件性许可并进入 BE-101 的商业发布。